Clinical trial · Interventional
Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)
Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic ductal adenocarcinoma (PDAC) has the poorest prognosis of all digestive cancers due to lack of early diagnosis and limited response to treatment. Patient-derived organoid technology has become a mainstay of precision oncology, enabling personalised functional characterisation of tumours (e.g. treatment evaluation and drug screening). Initial research carried out as part of the Cancer Profile project has produced the first organoids from resected PDAC parts. Only 15-20% of patients can benefit from surgical resection, which remains the only curative treatment. In contrast, most patients with PDAC undergo diagnostic fine-needle biopsies (FNB) using an echo-endoscopic procedure (EUS). The next step is therefore the reliable generation of organoids from limited quantities of biopsy material obtained by 'EUS-FNB'. The aim of the study presented here is to validate these organoids on the basis of the following characteristics: (i) morphological and proliferative characteristics, (ii) recapitulation of the genetic characteristics of the original tumour, (iii) expression of tumour markers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| PDAC - Pancreatic Ductal Adenocarcinoma | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sampling | Biological | — | UNRESOLVED |
| FNB sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FNB and blood sample analysis
- interventionNames
- Other: FNB sampling
- Biological: blood sampling
Primary outcomes (1)
- measure
- Organoid culture from PDAC EUS-FNB biopsy
- timeFrame
- 8 weeks
- description
- Qualitative assessment in the obtention of organoids. The main objective will be validated when a culture of functional organoids is generated.
Secondary outcomes (3)
- measure
- Evaluation of the protocol for culturing organoids derived from PDAC EUS-FNB biopsies.
- timeFrame
- 3 months
- description
- Evaluation of the mutations found in the organoid from the EUS-FNB biopsies compared to those in the original sample preserved in liquid nitrogen (qualitative criterion).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patient over 18 years of age. * Patient undergoing echo-endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB). * Suspicion of pancreatic lesion * Patient able to receive and understand information relating to the research protocol and to give consent. * Patient affiliated to the French social security system. Exclusion Criteria: * Patient not programmed for endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB). * Patient undergoing echo-endoscopy and presenting a high risk that may prevent EUS-FNB. * Patient with degenerated Intraductal papillary mucinous neoplasm (IPMN) * Patient with acute pancreatitis within 4 weeks prior to EUS * Pregnant or breast-feeding patient * Patient under court protection. * Patient under guardianship or curatorship. * Patient in a situation of social vulnerability. * Patient under legal protection or unable to express his/her opposition.
References
Publications (0)
Data not yet available